Bar charts showing the numbers of significantly differentially expressed genes for the different contrasts. by Gillian P. McHugo (8965919)

Everolimus decreased CD89 deposits in α1^KICD89^Tg mice. by Alexandra Cambier (22307216)

Change in Watt’s Connectedness Scale, Subscales by Treatment Group. by Benjamin R. Lewis (22279166)

Subjects:

Primary and secondary efficacy end points (intention-to-treat population). by Benjamin R. Lewis (22279166)

Subjects:

Demographic and clinical characteristics of participants at baseline. by Benjamin R. Lewis (22279166)

Subjects:

Study-related adverse events. by Benjamin R. Lewis (22279166)

Subjects:

Study flow chart. by Benjamin R. Lewis (22279166)

Subjects:

Change in QIDS-SR-16 and MBI-HSS-MP by Treatment Group. by Benjamin R. Lewis (22279166)

Subjects:

Study CONSORT diagram. by Benjamin R. Lewis (22279166)

Subjects:

Change in Demoralization Scale (DSII) by Treatment Group. by Benjamin R. Lewis (22279166)

Subjects:

Change in Watt’s Connectedness Scale (WCS), General Connectedness by Treatment Group. by Benjamin R. Lewis (22279166)

Subjects:

Variation of the most appropriate p value significance threshold with different ratios of the standard deviations and sample sizes. by Farrokh Habibzadeh (12256529)

Fig 1 - by Farshid Maleki (20521649)

Subjects:

Fig 8 - by Farshid Maleki (20521649)

Subjects:

Schematic presentation of mechanism of anti-cancer activity of ATO and GCB combination in breast cancer cells. by Farshid Maleki (20521649)

Subjects:

Fig 4 - by Farshid Maleki (20521649)

Subjects:

Fig 9 - by Farshid Maleki (20521649)

Subjects:

Trypan blue dye exclusion assay for cell viability evaluation (% of control). by Farshid Maleki (20521649)

Subjects:

Fig 7 - by Farshid Maleki (20521649)

Subjects:

Rate of apoptosis in MDA-MB-231 cells (ATO: 2.5 μM and GCB: 22.5 μM, 48 h, at 37°C). by Farshid Maleki (20521649)

Subjects: